Document:

<PAGE>

                                                                   Exhibit 10.32
                                                                   -------------

                                AMENDMENT NO. 2
                                ---------------
                                      TO
                                      --
                            KIRIN-AMGEN, INC./AMGEN
                            -----------------------
                       G-CSF EUROPEAN LICENSE AGREEMENT
                       --------------------------------

         THIS AMENDMENT NO. 2 ("Amendment No. 2") TO THAT CERTAIN KIRIN-AMGEN,
INC./AMGEN G-CSF EUROPEAN LICENSE AGREEMENT ("License Agreement"), is made and
entered into this 15th day of March, 1988, by and between AMGEN INC., a Delaware
corporation ("Amgen"), and KIRIN-AMGEN, INC., a California corporation
("Corporation").

                                R E C I T A L S
                                - - - - - - - -

         A. Amgen and Corporation have previously executed that certain License
Agreement regarding G-CSF and Amendment No. 1

         B. The parties desire to incorporate certain changes into the License
Agreement pursuant to this Amendment No . 2.

         NOW, THEREFORE, it is agreed as follows:

1.       Article II, Section 2.03(c) at page 5 of the License Agreement is
hereby amended as follows:

         "1)   $500,000 (U.S.) - Demonstration of the utility
               of G-CSF as an adjunct to chemotherapy.

         2)    $500,000 (U.S.) - Finalization of Phase III protocol
               and completion of investigators meeting.

         3)    $500,000 (U.S.) - Due on 30 days after the filing of
               Registration in any country in the Territory, provided
               such filing has not been rejected within the
               intervening period. If the filing is rejected within
               the intervening period, the amount will become due upon
               filing the corrected Registration."

2.        Except to the extent as provided herein, the provisions of the License
Agreement, as amended, are hereby ratified and confirmed in all respects.

<PAGE>

      In WITNESS WHEREOF, the undersigned have caused this Amendment No. 2 to be
executed as of the first day written above.

                                    AMGEN INC.,
                                    a Delaware corporation

                                    By /s/ George B. Rathmann
                                       -----------------------------------------
                                      George B. Rathmann, President
                                                            "Amgen"

                                    KIRIN  -AMGEN, INC.,
                                    a California corporation

                                    By /s/ Y.   Yamamoto
                                       -----------------------------------------
                                       Yashushi Yamamoto, Chairman
                                                           "Corporation"

                                      -2-
<PAGE>

                             [LETTERHEAD OF KIRIN]

                                                       April 1, 1988

Mr. Robert D. Weist
Senior Vice President
Amgen, Inc.
1900 Oak Terrace Lane
Thousand Oaks, CA 91320
U.S.A.

Dear Bob:

As per your request, we will send you by faxcimile a copy of letter agreement
for G-CSF registration milestone amendment with Dr. Yamamoto's signature.

We will send you the original letter by separate mail.

Formal documentation should be executed at the coming Board of
Directors Meeting on April 15, 1988.

                                 Sincerely yours,

                                  /s/ Toshikazu Doi
                                  -----------------
                                  Toshikazu Doi
                                  Pharmaceuticals Dept.

cc:  Mr. G. Binder
     Mr. L. Sears
     Mr. K. Aramaki
<PAGE>

Amgen and Kirin agree that Section 2.03(c) of the G-CSF European
License Agreement between Kirin-Amgen and Amgen should be amended so
that the milestone be payable as follows:

  1)$500,000 (U.S.) - Demonstration of the utility of G-CSF
     as an adjunct to chemotherapy.

  2)$500,000 (U.S.) - Finalization of Phase III protocol and
     completion of investigators meeting.

  3)$500,000 (U.S.) - Due on 30 days after the filing of
     Registration in any country in the Territory, provided
     such filing has not been rejected within the
     intervening period. If the filing is rejected within
     the intervening period, the amount will become due upon
     filing the corrected Registration.

                                   /s/ George B. Rathmann
                                   -------------------------------------
                                   George B. Rathmann, Amgen Inc.

                                   /s/ Y. Yamamoto
                                   -------------------------------------
                                   Kirin Brewery Company, Ltd.<PAGE>

                                                                   Exhibit 10.33
                                                                   -------------

                                AMENDMENT NO. 3
                                ---------------
                                      TO
                                      --
                            KIRIN-AMGEN, INC./AMGEN
                            -----------------------
                       G-CSF EUROPEAN LICENSE AGREEMENT
                       --------------------------------

          THIS AMENDMENT N0. 3 ("Amendment No. 3") TO THAT CERTAIN KIRIN-AMGEN,
INC./AMGEN G-CSF EUROPEAN LICENSE AGREEMENT ("License Agreement"), is made and
entered into this 20th day of October, 1988, by and between AMGEN INC., a
Delaware corporation ("Amgen"), and KIRIN-AMGEN, INC., a California corporation
("Corporation").

                                 R E C I T A L S
                                 ---------------

          A. Amgen and Corporation have previously executed that certain License
Agreement regarding G-CSF and Amendment Nos. 1 and 2.

          B. The parties desire to incorporate certain changes into the License
Agreement pursuant to this Amendment No. 3.

          NOW,  THEREFORE, it is agreed as follows:

1.        Article I, Section 1.08 at page 3 of the License Agreement is hereby
deleted and the following substituted in lieu thereof:

               "Sales Value. `Sales Value' shall mean the amount billed by
                -----------
          Amgen or an affiliate from the sale for commercial use of G-CSF
          Products to independent third parties less the following amounts
          included in the billed amount: (i) discounts, including cash
          discounts, or rebates actually allowed or granted from the billed
          amount, (ii) credits or allowances actually granted upon claims or
          returns regardless of the party requesting the return, (iii) freight
          charges paid for delivery, and (iv) taxes or other government charges
          levied on or measured by the billed amount whether absorbed by the
          billing or the billed party."

2.        Exhibit "A" attached hereto listing the countries of Europe which
comprise the Territory of Europe shall be substituted in lieu of the map of the
Territory of Europe attached as Exhibit "A" to the License Agreement.

3.        Except to the extent as provided herein, the provisions of the License
Agreement, as amended, are hereby ratified and confirmed in all respects.

<PAGE>

     IN WITNESS WHEREOF, the undersigned have caused this Amendment No. 3 to be
executed as of the first day written above.

                                          AMGEN INC.,
                                          a Delaware corporation

                                          By /s/ George B. Rathmann
                                             --------------------------------
                                             George B. Rathmann, President
                                                                      "Amgen"

                                          KIRIN-AMGEN, INC.,
                                          a California corporation

                                          By /s/ Yashushi Yamamoto
                                             --------------------------------
                                             Yashushi Yamamoto, Chairman
                                                                "Corporation"

                                      -2-
<PAGE>

                             COUNTRIES COMPRISING
                                      THE
                              TERRITORY OF EUROPE
                              -------------------

                                  EXHIBIT "A"<PAGE>

                                                                   Exhibit 10.34
                                                                   -------------
                                AMENDMENT NO. 4
                                ---------------
                                      TO
                                      --
                            KIRIN-AMGEN, INC./AMGEN
                            -----------------------
                       G-CSF EUROPEAN LICENSE AGREEMENT
                       --------------------------------

                   THIS AMENDMENT NO. 4 ("Amendment No. 4") TO THAT CERTAIN
   KIRIN-AMGEN, INC./AMGEN G-CSF EUROPEAN LICENSE AGREEMENT ("License
   Agreement"), is made and entered into this 29/TH/ day of December, 1989, by
   and between AMGEN INC., a Delaware corporation ("Amgen") and KIRIN-AMGEN,
   INC., a California corporation ("Corporation").

                                R E C I T A L S
                                - - - - - - - -

                   A. Amgen and Corporation have previously executed that
   certain License Agreement regarding G-CSF and Amendment Nos. 1, 2 and 3.

                   B.   The parties desire to incorporate certain changes into
   the License Agreement pursuant to this Amendment No. 4.

                   NOW, THEREFORE, it is agreed as follows:

   1.              Article II, Section 2.03(d) and (e) at page 5 of the License
   Agreement are hereby deleted and the following substituted in lieu thereof:

                   "(d)  $3,000,000 (U.S.) -- Filing of a Product Licensing
                         Application in the United States."

   2.              Except to the extent as provided herein, the provisions of
   the License Agreement, as amended, are hereby ratified and confirmed in all
   respects.

                   IN WITNESS WHEREOF, the undersigned have caused this
   Amendment No. 4 to be executed as of the first day written above.

                                      AMGEN INC., a Delaware
                                      corporation

                                      By   /s/ Gordon M. Binder
                                           ------------------------------
                                           Gordon M. Binder, Chief
                                           Executive Officer

                                                                      "Amgen"

                                      KIRIN-AMGEN, INC.,
                                      a California corporation

                                      By   /s/ Y. Yamamoto
                                           ------------------------------
                                           Yashushi Yamamoto, Chairman

                                                                   "Corporation"

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00020-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00020-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00020-of-00352.parquet"}]]